Ivosidenib is the first-in-class FDA approval for IDH1 mutation-harboring acute myeloid leukemia.
Clinical stage determined by the Binet staging system could be an accurate response surrogate among patients with chronic lymphocytic leukemia.
Evidence for the impact of obesity on outcomes for bladder cancer have been conflicting and require further study.
Previous studies have suggested that analgesic medicine use may have a protective effect for patients with ovarian cancer.
The FDA based its approval on the results of a triplet of phase 3 studies, the MONALEESA-2, MONALEESA-3, and MONALEESA-7.
Twenty-three systemic therapy-naive patients with advanced hepatocellular carcinoma received atezolizumab plus bevacizumab every 3 weeks.
Close postmarketing monitoring will be especially crucial for drugs approved with a breakthrough therapy designation, as many of them were given a pass on the basis of a single pivotal trial.
Evidence from previous studies have demonstrated that combined modality therapy with chemotherapy and radiotherapy may improve long-term outcomes in this patient population.
A study investigating the effects of adjuvant chemotherapy showed that treatment improved metastases-free survival and overall survival among patients with soft-tissue sarcoma and high-risk factors.
Drug developers relying on CRISPR-Cas9 platforms for the creation of gene therapies saw their shares slide when it was revealed that the technique may inadvertently cause disruptions of larger chunks of DNA than previously thought.
Social media has become a popular networking and marketing platform for oncologists. Here's what to do and what not to do on social media.
Only a few studies have investigated the effectiveness of pazopanib and cetuximab, an angiogenesis inhibitor and EGFR inhibitor, respectively, for head and neck squamous cell carcinoma.
This latest approval now makes enzalutamide the only FDA-approved oral medication indicated for both metastatic and nonmetastatic castration-resistant prostate cancer.
Variations in the use and frequency of advanced imaging post-surgery in patients with breast cancer were observed across regions of the United States.
The anti-programmed death 1 (PD-1) antibody pembrolizumab was determined to be an effective second-line option for patients with head and neck cancers.
Although they fall outside official testing guidelines for lung cancer, people who have smoked at all in their lifetime could still be at risk for the disease. Researchers propose a biomarker test for 4 proteins could identify more individuals that could benefit from subsequent screening.
For this phase 1b study, researchers enrolled 57 patients with ERBB2/HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.
Updated results of the SOFT and TEXT trial suggest that adding ovarian suppression to exemestane or tamoxifen could improve survival outcomes.
The FDA based its approval on evidence from the ongoing, non-randomized CheckMate-142 phase 2 study, for which researchers treated 119 patients with nivolumab plus ipilimumab.
According to recent research, scientists may not need to rely on the use of viral vectors to edit the genes of primary immune cells when creating cell and gene therapies.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- FDA Approves Ivosidenib for IDH1-Mutated Relapsed/Refractory Acute Myeloid Leukemia
- Clinical Stage at First Response May Predict Outcomes in Chronic Lymphocytic Leukemia
- Exercise and Cancer
- Increased Body Mass Index May Be Predictive of Recurrence, Progression in Bladder Cancer
- Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer